Literature DB >> 18582964

Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?

Rui Chen1, Fengxia Liang, Junji Moriya, Jun-ichi Yamakawa, Takashi Takahashi, Lin Shen, Tsugiyasu Kanda.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) alpha and gamma regulate nearly every step in cellular fatty acid uptake, utilization, oxidation, and storage pathways. They also control cell growth and migration, oxidative stress, and inflammation in the cardiovascular system. Recent studies have shown that PPARs have paradoxical effects on cardiovascular diseases, especially hypertension and heart failure. It is still unclear whether the blood pressure increases or decreases after treatment with a PPAR alpha agonist; it is also uncertain whether PPAR agonists are beneficial or harmful for heart failure. In order to clarify these issues, the literature on PPAR alpha and gamma and their agonists, as well as their effect on hypertension and heart failure not only in humans but also in experimental animals, was reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582964     DOI: 10.1016/j.ijcard.2008.03.080

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

Review 2.  Mitochondrial protein phosphorylation as a regulatory modality: implications for mitochondrial dysfunction in heart failure.

Authors:  Brian O'Rourke; Jennifer E Van Eyk; D Brian Foster
Journal:  Congest Heart Fail       Date:  2011-11-09

3.  Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function.

Authors:  Raquel Hernanz; Ángela Martín; Jose V Pérez-Girón; Roberto Palacios; Ana M Briones; Marta Miguel; Mercedes Salaices; María J Alonso
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

5.  n-3 PUFA as regulators of cardiac gene transcription: a new link between PPAR activation and fatty acid composition.

Authors:  Mattia Di Nunzio; Francesca Danesi; Alessandra Bordoni
Journal:  Lipids       Date:  2009-10-27       Impact factor: 1.880

6.  Prediction and Subtyping of Hypertension from Pan-Tissue Transcriptomic and Genetic Analyses.

Authors:  Mahashweta Basu; Mahfuza Sharmin; Avinash Das; Nishanth Ulhas Nair; Kun Wang; Joo Sang Lee; Yen-Pei Christy Chang; Eytan Ruppin; Sridhar Hannenhalli
Journal:  Genetics       Date:  2017-09-12       Impact factor: 4.562

Review 7.  Peroxisome proliferator-activated receptors for hypertension.

Authors:  Daisuke Usuda; Tsugiyasu Kanda
Journal:  World J Cardiol       Date:  2014-08-26

8.  Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

Authors:  Hiroshi Hasegawa; Hiroyuki Takano; Issei Komuro
Journal:  PPAR Res       Date:  2010-08-12       Impact factor: 4.964

9.  Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.

Authors:  Wei-Li Zhang; Wen-Ju Yan; Bei Sun; Zhi-Peng Zou
Journal:  Lipids Health Dis       Date:  2014-10-31       Impact factor: 3.876

Review 10.  Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.

Authors:  Wang-Soo Lee; Jaetaek Kim
Journal:  PPAR Res       Date:  2015-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.